Investigators at Pfizer Report Findings in Immunoglobulins (Anti-drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route).
In: Drug Week, 2024-06-07, S. 1030-1030
serialPeriodical
Zugriff:
A recent study conducted by investigators at Pfizer compared the immunogenicity of therapeutic proteins administered via subcutaneous (SC) and intravenous (IV) routes of administration (RoA). The study analyzed data from 48 treatment groups and found that there was no significant difference in the incidence of anti-drug antibodies (ADA) between the two routes of administration. The study concluded that there is no significant difference in ADA incidence between SC and IV RoA for the 17 therapeutic proteins analyzed. This research has been peer-reviewed and published in The AAPS Journal. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Investigators at Pfizer Report Findings in Immunoglobulins (Anti-drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route).
|
---|---|
Zeitschrift: | Drug Week, 2024-06-07, S. 1030-1030 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|